Epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an intensive care unit with no single rooms.

Ann Intensive Care

Intensive Care Unit, Section Thorax-Vascular Disease-Abdomen-Metabolism, Assistance Publique-Hôpitaux de Paris, University Hospital Ambroise Paré, 9, Avenue Charles-de-Gaulle, 92100, Boulogne-Billancourt, France.

Published: December 2017

Background: The transmission of extended-spectrum beta-lactamase-producing enterobacteriaceae (ESBL) is prevented by additional contact precautions, mainly relying on isolation in a single room and hand hygiene. Contact isolation cannot be achieved in our 12-bed ICU, which has only double rooms. We report the epidemiology of ESBL imported, acquired and transmitted in an ICU with no single rooms.

Methods: We prospectively conducted an observational and non-interventional study in a French 12-bed ICU. Inclusion criteria were patients >18 years of age treated by at least two successive nursing teams. Patient characteristics at admission and clinical data during hospital stay were collected prospectively. ESBL carriage was monitored using rectal swabs collected at admission and once weekly during the ICU stay. Potential cross-transmission was studied (1) by identifying index patients defined as possible ESBL sources for transmission, (2) by classifying each ESBL strain according to the cefotaximase München (CTX) 1 and 9 groups and (3) by gene sequencing for remaining cases of possible transmission.

Results: From June 2014 to April 2015, of 550 patients admitted to the ICU, 470 met the inclusion criteria and 221 had at least two rectal swabs. The rate of ESBL colonization, mainly by Escherichia coli, at admission was 13.2%. The incidence of ESBL acquisition, mainly with E. coli too, was 4.1%. Mortality did not differ between ESBL carriers and non-carriers. In univariate analysis, ESBL acquisition was associated with male gender, SAPS II, SOFA, chronic kidney disease at admission, duration of mechanical ventilation, need for catecholamine and the ICU LOS. In multivariate analysis, SAPS II at admission was the only risk factor for ESBL acquisition. We confirmed cross-transmission, emanating from the same index patient, in two of the nine patients with ESBL acquisition (0.8%, 2/221). No case of cross-transmission in the same double room was observed.

Discussion And Conclusion: Prevalence of ESBL colonization in our ICU was 13.2%. Despite the absence single rooms, the incidence of ESBL acquisition was 4.1% and cross-transmission was proven in only two cases, resulting from the same index patient who was not hospitalized in the same double room.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495817PMC
http://dx.doi.org/10.1186/s13613-017-0295-0DOI Listing

Publication Analysis

Top Keywords

esbl acquisition
20
esbl
13
extended-spectrum beta-lactamase-producing
8
beta-lactamase-producing enterobacteriaceae
8
single rooms
8
12-bed icu
8
inclusion criteria
8
rectal swabs
8
esbl colonization
8
incidence esbl
8

Similar Publications

Background: The impact of community carriage on the influx of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) into hospitals remains understudied. In this prospective 2-year single-centre study, we investigate the community ESBL-E influx and trace the colonisation, nosocomial acquisition, transmission, and infection dynamics of ESBL-producing Escherichia coli (ESBL-Ec) in non-ICU wards at a tertiary care hospital.

Methods: This study reports primary and post hoc outcomes of the clinical trial NCT01208519 in which hospitalised patients were screened for rectal carriage of ESBL-E.

View Article and Find Full Text PDF

Background: The emergence and spread of Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia coli pose significant challenges for treatment of infections globally. This challenge is exacerbated in sub-Saharan African countries, where the prevalence of ESBL-producing E. coli is high.

View Article and Find Full Text PDF

Community-acquired urinary tract infections account for 15% of all outpatient use of antibiotics, and women are primarily affected; the major causative microorganism is uropathogenic (). Treatment is indicated for cystitis and pyelonephritis and includes B-lactams (amoxicillin-clavulanic acid or third-generation cephalosporins), fluoroquinolones (ciprofloxacin or levofloxacin), nitrofurantoin, fosfomycin, and trimethoprim-sulfamethoxazole. Resistance to antibiotic treatment is of concern; several mechanisms have been associated with the acquisition of genes that confer antimicrobial resistance to fluoroquinolones, which are often associated with other patterns of resistance, especially in extended-spectrum beta-lactamase (ESBL) producers.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the prevalence and risk factors of extended-spectrum beta-lactamase (ESBL)-producing bacteria in children hospitalized for urinary tract infections (UTIs) at a hospital in Saudi Arabia from 2018 to 2022.
  • Out of 242 urine samples analyzed, 20.7% of the isolates were found to be ESBL producers, with previous antibiotic usage and recurrent UTIs identified as significant risk factors.
  • The ESBL-producing bacteria showed high resistance rates to ampicillin and third-generation cephalosporins, but were universally sensitive to meropenem, highlighting the need for better antibiotic management in high-risk pediatric cases.
View Article and Find Full Text PDF
Article Synopsis
  • * Resistance rates for key antibiotics were significant, with 36.67% for cefotaxime, 21.67% for ciprofloxacin, and 10.00% for azithromycin; additionally, 23.33% of the strains produced extended-spectrum beta-lactamases (ESBLs).
  • * The study highlighted the genetic basis of resistance, identifying specific resistance genes and plasmids, and demonstrated
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!